Curio Digital Therapeutics, a company specializing in digital therapeutics for women’s health, has raised a ‘double digit million’ investment in its latest funding round. The round included investments from RYSE Asset Management, ONCE (the nutraceuticals venture capital arm of Otsuka), Bridge Point Capital, and Avestria.
Curio, based in New Jersey, focuses on addressing mental health conditions such as postpartum depression (PPD) through digital therapeutic solutions. The company’s main product, MamaLift Plus, has received FDA approval as a Software as a Medical Device (SaMD) Class 2, making it the first prescription digital therapeutic for the treatment of postpartum depression. MamaLift Plus is intended for women aged 22 years and older and is administered over an eight-week period in conjunction with clinician-managed outpatient care.
Postpartum depression affects approximately one in seven women after childbirth. MamaLift Plus is supported by a Connected Care platform, which assesses a woman’s risk of depression and coordinates treatment with her healthcare providers. This feature is particularly relevant for healthcare providers who report on depression levels among their female patients.
Curio is collaborating with health plans, insurers, and corporate employee benefit plans in the US and India, and is also working with pharmaceutical companies and other partners to utilize its data and Connected Care platform. This platform covers postpartum depression, fertility, and menopause, providing comprehensive care throughout various stages of women’s health.
Shailja Dixit, MD, MPH, MS, CEO and Founder of Curio Digital Therapeutics, said, “Our goal has always been to provide innovative solutions for women’s health, specifically around the challenges they face with behavioral health. MamaLift Plus is the first and only digital solution that can help address the serious unmet need uniquely faced by women who have recently delivered, and help make a conscious shift in women’s health. We are grateful to have the backing of RYSE, and our committed new investors as we bring these products to new markets.”
The investment will support Curio’s ongoing commercialization efforts, particularly with health plans and insurers in the US, UK, and India. It will also help advance Curio’s pipeline of women’s health products.
Vivien de Tusch-Lec, General Partner at RYSE Asset Management, added, “As a clinically validated, fully scalable, revenue-generating solution, Curio is taking a holistic approach to addressing women’s health by designing interventions that address behavioral management and physiological conditions across Women’s Life Cycle. We see a significant opportunity for MamaLift Plus, and for the other products in the Company’s pipeline.”
